Melanoma Matters
Melanoma Matters
Podcast Description
From the UK to the USA - Melanoma Matters is on a mission!
Hosts James Larkin and Sapna Patel are spreading the word on melanoma, one podcast at a time. Tune in for a critical review of the literature and a discussion of how we incorporate the data into our practices...across the pond(s).
#MelanomaMatters video podcast
Podcast Insights
Content Themes
The podcast covers a wide range of melanoma-related topics, including immune therapies, clinical trial results, and updates from major medical conferences. Notable episodes examine studies like the CheckMate 067 and the implications of the ADAPT-IT study on treatment strategies, alongside discussions about patient care and systemic challenges in accessing effective therapies.
From the UK to the USA – Melanoma Matters is on a mission!
Hosts James Larkin and Sapna Patel are spreading the word on melanoma, one podcast at a time. Tune in for a critical review of the literature and a discussion of how we incorporate the data into our practices…across the pond(s).
#MelanomaMatters video podcast
Summary
In this conversation, James Larkin and Sapna Patel discuss the consensus definitions for resistance to immune checkpoint inhibitors, focusing on a recent paper from the Journal of Immunotherapy of Cancer. They explore the complexities of primary and secondary resistance, the importance of defining these terms for clinical trials, and the challenges in trial design and control arms. The discussion emphasizes the need for clear definitions to improve patient outcomes and guide future research in oncology.
Keywords
immune checkpoint inhibitors, cancer treatment, resistance, clinical trials, melanoma, PD-1, adjuvant therapy, response rate, tumor sensitivity, oncology
Takeaways
Resistance to immune checkpoint inhibitors is a major challenge in melanoma treatment.
Primary resistance occurs when there is no benefit from treatment, while secondary resistance follows initial benefit.
Defining resistance is crucial for clinical trials and understanding patient populations.
The duration of drug exposure is key in determining resistance types.
Clinical trial design must consider the expectations of efficacy in control arms.
Investigators should be cautious about the definitions of patient populations in trials.
Response rates of 15-20% are considered significant for primary resistance.
Secondary resistance may show higher response rates due to residual sensitivity.
Clear definitions help in layering data for future research.
Collaboration among clinicians, industry, and regulatory bodies is essential for advancing cancer treatment.
Sound Bites
“It’s probably the biggest challenge we now have in clinic.”
“There’s something in the middle.”
“I think that’s where we might need to be there.”
Chapters
00:00 Introduction to Immune Checkpoint Inhibitors and Resistance
08:08 Understanding Resistance: Definitions and Scenarios
14:47 Primary vs. Secondary Resistance in Clinical Trials
22:00 Trial Design and Control Arms in Immunotherapy
30:36 Conclusions and Future Directions
33:28 outro fade long expo.mp4
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.